Co-treatment with 3-MA or overexpression of Cdc25A upregulated p62 and FTH1 levels and downregulated the LC3-II/LC-I ratio and TfR1 level in sorafenib-treated cells (Fig. 5A), indicating that overexpression of Cdc25A suppressed sorafenib-induced autophagy in cervical cancer cells. The gene discussed is MAP1LC3A; the disease is cervical carcinoma.